86 related articles for article (PubMed ID: 16524789)
1. Acid-suppressive effects of generic omeprazole: comparison of three brands of generic omeprazole with original omeprazole.
Shimatani T; Inoue M; Kuroiwa T; Xu J; Mieno H; Tazuma S
Dig Liver Dis; 2006 Aug; 38(8):554-9. PubMed ID: 16524789
[TBL] [Abstract][Full Text] [Related]
2. Generic versus brand-name medicinal products: are they really interchangeable?
Motola D; De Ponti F
Dig Liver Dis; 2006 Aug; 38(8):560-2. PubMed ID: 16731062
[No Abstract] [Full Text] [Related]
3. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
Shimatani T; Inoue M; Kuroiwa T; Xu J; Mieno H; Nakamura M; Tazuma S
Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
[TBL] [Abstract][Full Text] [Related]
4. Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers.
Shimatani T; Inoue M; Kuroiwa T; Moriwaki M; Xu J; Ikawa K; Morikawa N; Tazuma S
Dig Dis Sci; 2007 Feb; 52(2):390-5. PubMed ID: 17211705
[TBL] [Abstract][Full Text] [Related]
5. Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status.
Sugimoto M; Furuta T; Shirai N; Ikuma M; Hishida A; Ishizaki T
Clin Pharmacol Ther; 2006 Nov; 80(5):539-48. PubMed ID: 17112810
[TBL] [Abstract][Full Text] [Related]
6. Intragastric acidity during administration of generic omeprazole or esomeprazole - a randomised, two-way crossover study including CYP2C19 genotyping.
Miehlke S; Löbe S; Madisch A; Kuhlisch E; Laass M; Grossmann D; Knoth H; Morgner A; Labenz J
Aliment Pharmacol Ther; 2011 Feb; 33(4):471-6. PubMed ID: 21175704
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy?
Inamori M; Togawa J; Takahashi K; Yoneda M; Fujisawa N; Iwasaki T; Ozawa Y; Kikuchi T; Muramatsu K; Chiguchi G; Matsumoto S; Kawamura H; Abe Y; Kirikoshi H; Kobayashi N; Sakaguchi T; Takamura T; Nakajima A; Ueno N; Sekihara H
J Gastroenterol Hepatol; 2003 Sep; 18(9):1034-8. PubMed ID: 12911659
[TBL] [Abstract][Full Text] [Related]
8. Early effects of oral administration of esomeprazole and omeprazole on the intragastric pH.
Iida H; Inamori M; Okuno K; Sekino Y; Sakai E; Okubo H; Higurashi T; Endo H; Hosono K; Yoneda M; Koide T; Takahashi H; Goto A; Kubota K; Saito S; Maeda S; Nakajima A; Gotoh E
Hepatogastroenterology; 2015; 62(138):493-6. PubMed ID: 25916088
[TBL] [Abstract][Full Text] [Related]
9. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans.
Furuta T; Ohashi K; Kosuge K; Zhao XJ; Takashima M; Kimura M; Nishimoto M; Hanai H; Kaneko E; Ishizaki T
Clin Pharmacol Ther; 1999 May; 65(5):552-61. PubMed ID: 10340921
[TBL] [Abstract][Full Text] [Related]
10. Comparing the acid-suppressive effects of three brands of generic lansoprazole with the original: pharmacokinetic bioequivalence tests do not necessarily guarantee pharmacodynamic equivalence.
Shimatani T; Hirokawa S; Tawara Y; Hamai K; Matsumoto M; Tazuma S; Inoue M
Dig Dis Sci; 2009 Nov; 54(11):2385-90. PubMed ID: 19093205
[TBL] [Abstract][Full Text] [Related]
11. Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status.
Furuta T; Shirai N; Sugimoto M; Nakamura A; Okudaira K; Kajimura M; Hishida A
Aliment Pharmacol Ther; 2005 Jul; 22(1):67-74. PubMed ID: 15963082
[TBL] [Abstract][Full Text] [Related]
12. Acid inhibition effect of ilaprazole on Helicobacter pylori-negative healthy volunteers: an open randomized cross-over study.
DU YQ; Guo WY; Zou DW; Zhan XB; Li Z; Hu JH; Gong YF; He J; Lu JP; Li ZS
J Dig Dis; 2012 Feb; 13(2):113-9. PubMed ID: 22257480
[TBL] [Abstract][Full Text] [Related]
13. Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes.
Roh HK; Kim PS; Lee DH; Tybring G; Sagar M; Park CS; Seensalu R; Bertilsson L
Basic Clin Pharmacol Toxicol; 2004 Sep; 95(3):112-9. PubMed ID: 15447734
[TBL] [Abstract][Full Text] [Related]
14. Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h.
Howden CW; Metz DC; Hunt B; Vakily M; Kukulka M; Amer F; Samra N
Aliment Pharmacol Ther; 2006 Apr; 23(7):975-84. PubMed ID: 16573800
[TBL] [Abstract][Full Text] [Related]
15. Acid-suppressive effects of various regimens of omeprazole in Helicobacter pylori-negative CYP2C19 homozygous extensive metabolizers: which regimen has the strongest effect?
Shimatani T; Kuroiwa T; Moriwaki M; Xu J; Tazuma S; Inoue M
Dig Dis Sci; 2007 Oct; 52(10):2826-32. PubMed ID: 17410461
[TBL] [Abstract][Full Text] [Related]
16. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans.
Furuta T; Ohashi K; Kobayashi K; Iida I; Yoshida H; Shirai N; Takashima M; Kosuge K; Hanai H; Chiba K; Ishizaki T; Kaneko E
Clin Pharmacol Ther; 1999 Sep; 66(3):265-74. PubMed ID: 10511062
[TBL] [Abstract][Full Text] [Related]
17. [Bioavailability of three brands of omeprazole capsule and their effects on 24 hour intragastric pH in healthy volunteers].
Dong H
Zhonghua Nei Ke Za Zhi; 1999 Aug; 38(8):533-6. PubMed ID: 11798692
[TBL] [Abstract][Full Text] [Related]
18. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.
Sheu BS; Kao AW; Cheng HC; Hunag SF; Chen TW; Lu CC; Wu JJ
Aliment Pharmacol Ther; 2005 Feb; 21(3):283-8. PubMed ID: 15691303
[TBL] [Abstract][Full Text] [Related]
19. Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects.
Bruley des Varannes S; Gharib H; Bicheler V; Bost R; Bonaz B; Stanescu L; Delchier JC; Bonnot-Marlier S
Aliment Pharmacol Ther; 2004 Oct; 20(8):899-907. PubMed ID: 15479362
[TBL] [Abstract][Full Text] [Related]
20. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
Sugimoto M; Furuta T; Shirai N; Kajimura M; Hishida A; Sakurai M; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2004 Oct; 76(4):290-301. PubMed ID: 15470328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
